ArticleBMC microbiology2025
Whole-genome analysis of Bacillus paranthracis YC06 isolated from healthy individual feces for biodegrading inosine and guanosine.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pathway and Mechanism for the Biodegradation of Inosine and Guanosine byFoods (Basel, Switzerland) · 2026Article
- Isolation and Mechanistic Characterization ofFoods (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The overproduction of uric acid, driven by its key precursors (inosine and guanosine), leads to hyperuricemia, a metabolic disorder associated with severe complications such as gout and renal dysfunction. Here, a promising bacterial strain YC06 with excellent biodegradation capability for inosine and guanosine was successfully isolated from healthy individual feces and identified as Bacillus paranthracis through average nucleotide identity (ANI) analysis. B. paranthracis YC06 resting cells (live but suspended in PBS buffer) and its cell-free extracts could effectively biodegrade inosine and guanosine in vitro. Whole-genome sequencing revealed a 5,535,183 bp draft genome (52 contigs, 35.22% GC content) containing 5,672 protein-coding genes. B. paranthracis YC06 demonstrated high survival rates in simulated gastrointestinal fluids, supported by the presence of stress-response genes and bile salt hydrolase genes associated with gastrointestinal tolerance. However, this strain exhibited hemolytic activity and no amino acid decarboxylase activity, while hemolysin genes, antibiotic genes and toxin-producing genes were identified, raising potential biosafety concerns for its further application. The gene functional annotation and polymerase chain reaction (PCR) amplification electrophoresis identified key genes (rihA, rihB, deoD and pnp) encoding purine nucleosidase and purine-nucleoside phosphorylase, and combined with biodegradation product analysis, elucidated the pathways of inosine and guanosine biodegradation into hypoxanthine and guanine. Comprehensive safety evaluations, including cytotoxicity assay and in vivo pathogenicity studies, must be conducted to rigorously assess its risks prior to practical utilization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.